U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 200 points on Friday.Following the market opening Friday, the Dow traded down 1.21% to 46,882.86 while the NASDAQ fell 1.51% to 22,525.90. The S&P 500 also fell, dropping, 1.17% to 6,658.51.Check This Out: Top 2 Financial Stocks That May Plunge This QuarterLeading and Lagging SectorsReal estate shares jumped by 0.3% on Friday.In trading on Friday, information technology stocks fell by 1.2%.Top HeadlineApplied Materials Inc (N ...

Core Insights - The company has sufficient cash and investments to fund current operations through Q2 2027, excluding VenoValve commercialization and the enVVe IDE study [1] - The cash burn for Q3 2025 was $4.2 million, which aligns with the projected quarterly range [1] - The company is engaged in an ongoing appeal with the FDA regarding the VenoValve PMA decision, with feedback anticipated by the end of 2025 [1] Financial Summary - The company ended Q3 2025 with $31.0 million in cash and investments [1]

Key Takeaways NVNO stock sank 76.1% after the FDA issued a not-approvable letter for VenoValve.The FDA flagged insufficient NVNO's SAVVE study data and raised surgical safety concerns.NVNO eyes an IDE filing for its non-surgical enVVe valve as the next pipeline step.Shares of enVVeno Medical (NVNO) have crashed 76.1% since Aug. 19. The significant decline was due to the FDA’s not-approvable letter in response to its Premarket Approval (“PMA”) application for Veno Valve.The company submitted the PMA applicat ...